REFLUX DISEASE GASTROINTESTINAL & HEPATOLOGY SOLUTIONS

DIAGNOSING REFLUX DISEASE

Gastroesophageal reflux disease (GERD) affects up to 40% of the U.S. population in their lifetime and is part of an increasingly significant public health burden.Early detection and treatment of GERD is essential, as a small percentage (10-15%) of patients with GERD develop Barrett’s esophagus.Barrett's esophagus is the primary risk factor for esophageal adenocarcinoma.3-9


BRAVO CALIBRATION-FREE REFLUX TESTING SYSTEM

Product image of Medtronic Bravo Calibration-Free Recorder against a light blue gradient background.

Many symptomatic patients with acid reflux do not understand the risks associated with chronic acid reflux. One in three patients referred with ongoing symptoms while using PPIs doesn’t have GERD.10

The Bravo™ calibration-free reflux testing system is a capsule-based, patient-friendly reflux test that measures acid levels in the esophagus to help you obtain an objective diagnosis of GERD.11,12


DIGITRAPPER PH AND IMPEDANCE TESTING SYSTEM

Product image of Medtronic Digitrapper pH and Impedance Testing System

Understand the root cause of reflux symptoms with pH and impedance testing using the Digitrapper™ pH and impedance testing system.

This catheter-based test:

  • Uses pH and impedance sensors to help identify the cause of esophageal or extraesophageal symptoms
  • Identifies all types of reflux events and measures their duration and acid content
  • Generally done when patient is taking PPIs
1

Vaezi M, Zehrai A, Yuksel E. Testing for refractory gastroesophageal reflux disease, ASGE Leading Edge. 2012;2(2):1-13.

3

Dymedex Market Development Consulting, GERD Sizing and Segmentation for pH Testing, February 13, 2015.

4

Gilbert EW, Luna RA, Harrison VL, Hunter JG. Barrett's esophagus: a review of the literature. J Gastrointest Surg. 2011;15:708-18.

5

Pohl H, Welch HG. The role of over diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-.

7

Dymedex Market Development Consulting, Strategic Market Assessment: Barrx-GI, October 30, 2014.

8

De Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut. 2010;59:1030-6.

9

Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011;365:1375-83.

10

Herregods, T. V. K., et al. Patients with refractory reflux symptoms often do not have GERD: Neurogastroenterology & Motility. 2015;27(9): 1267-1273.

11

Sharma VK. The future is wireless: advances in wireless diagnostic and therapeutic technologies in gastroenterology. Gastroenterol. 2009:137(2):434-439.

12

Medtronic. Bravo™ reflux testing system instructions for use (IFU). DOC-4009-01. 2017.

*

Image does not represent all components of the system